Nexalin Secures 10-Year Exclusive Distribution Deal for South America
NXL has more than doubled off its 52-week low of $4 on elevated volume (62× avg).
Summary
Nexalin Technology signed a 10-year exclusive distribution agreement for its Nexalin Sync device across seven South American countries, with a binding initial order for 5 devices and a distributor-funded local manufacturing plan.
Key Events · M&A and Partnerships · NXL
-
Exclusive 10-Year Distribution Agreement
Nexalin appointed Inovanexa Medical Technologies S.A. as exclusive distributor for the Nexalin Sync device across Brazil, Argentina, Chile, Uruguay, Paraguay, Ecuador, and Venezuela — a territory of over 300 million people.
-
Binding Initial Order of 5 Devices
The distributor must place an immediate binding purchase order for 5 Nexalin Sync devices, with a clinical pilot program in Brazil targeted to launch within 90 days, and an additional 5 devices within 12 months of the pilot.
-
100-Device Commercialization Program
The agreement establishes tiered per-device pricing for the first 100 devices, with no obligation for the distributor to purchase beyond the initial 10-device commitment unless performance requirements are met.
-
Distributor-Funded Local Manufacturing
Upon purchase of the first 30 devices, the distributor must establish a local manufacturing facility in Brazil at its own cost, with Nexalin receiving fixed per-device compensation and per-unit royalties on locally manufactured disposables.
Analysis · NXL · Industrial Applications And Services
A pre-revenue company facing a going-concern warning and Nasdaq delisting risk, Nexalin Technology has secured a 10-year exclusive distribution agreement covering seven South American countries. The deal includes a binding initial order for 5 devices, a 100-device commercialization program, and a distributor-funded local manufacturing facility in Brazil. This marks the company's first concrete path to commercial revenue, but the economics are heavily back-loaded: only 5 devices are committed at signing, and all future revenue depends on the distributor meeting performance requirements and funding manufacturing. Against a backdrop of dwindling cash ($1.0M as of last 10-Q) and a recent reverse split, this agreement is a meaningful but unproven lifeline.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1605 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXL was trading at $8.02 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $4.00 to $60.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.